Compare Danaher Corporation (DHR) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Enovix Corporation — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while Enovix Corporation trades at $2.56 (market cap $549.72M). The key difference: Danaher Corporation is far larger — about 278.1× Enovix Corporation's market cap, and Danaher Corporation pays a 0.74% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Enovix Corporation for 11 Days on average.
| DHR | ENVX | |
|---|---|---|
Market Cap | $152.87B | $549.72M |
Volume | 5,228,698 | 6,635,687 |
Sector | Health | Industrials |
52-Week High | $242.05 | $13.19 |
52-Week Low | $161.91 | $2.50 |
Typical Hold Time | 69 Days | 11 Days |
Enterprise Value | $175.08B | $611.42M |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
ENVX trades at $2.55, down 5.56% on the day, reflecting a bearish technical outlook with significant selling pressure indicated by moving averages and oscillators. Fundamentally, the company is in a high-growth, pre-profitability phase, with revenue growing to $36 million in 2026 but net losses widening to -$170 million. Recent news is dominated by a sudden CEO resignation in August 2026, though the company reaffirmed its strategy and operational guidance.
The investment case hinges on the company's advanced battery technology and expansion plans, particularly in the defense and drone sectors, against a backdrop of persistent cash burn and high execution risk. Analyst consensus remains bullish with a $10.75 price target, but the stock faces near-term volatility from leadership uncertainty and the challenging path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
